Why the study?
Do liposome-based drug-delivery systems reduce cardiotoxicity compared to conventional doxorubicin in patients receiving chemotherapy?
Do liposome-based drug-delivery systems reduce cardiotoxicity compared to conventional doxorubicin in patients receiving chemotherapy?
Liposomal formulations of doxorubicin provide a strategy to reduce the cumulative and irreversible cardiotoxicity associated with conventional doxorubicin therapy.
No takes yet. Share an insight, caveat, or question.
Supports consideration of pegylated liposomal doxorubicin to limit cardiotoxicity; leaves open need for prospective randomized confirmation.
Tahover et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: